BB
CDTX

BB Biotech’s Cidara Therapeutics CDTX Stock Holding History

BB Biotech’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$6.08M Hold
114,764
– – 0.15% 33
2018
Q4 		$5.39M Hold
114,764
– – 0.17% 34
2018
Q3 		$10.1M Hold
114,764
– – 0.27% 30
2018
Q2 		$11.9M Hold
114,764
– – 0.34% 30
2018
Q1 		$9.18M Hold
114,764
– – 0.25% 29
2017
Q4 		$15.6M Buy
114,764
+48,000
+72% +$7.28M 0.44% 27
2017
Q3 		$10.8M Buy
66,764
+11,635
+21% +$1.66M 0.3% 25
2017
Q2 		$8.27M Buy
55,129
+2,938
+6% +$406K 0.25% 27
2017
Q1 		$8.14M Hold
52,191
– – 0.27% 28
2016
Q4 		$10.9M Buy
52,191
+14,850
+40% +$3.09M 0.4% 25
2016
Q3 		$8.55M Hold
37,341
– – 0.3% 29
2016
Q2 		$7.7M Hold
37,341
– – 0.3% 29
2016
Q1 		$9.48M Buy
37,341
+14,007
+60% +$3.23M 0.38% 28
2015
Q4 		$8.01M Buy
+23,334
New +$7.01M 0.23% 29

Other funds holding CDTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $195M AUM 51.17% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

BB Biotech's CDTX Position: Q1 2019 in Review

BB Biotech held its Cidara Therapeutics (CDTX) position steady in Q1 2019 at 114,764 shares worth $6.08M. The position accounts for 0.15% of the portfolio, ranked #33.

BB Biotech first reported a position in CDTX in Q4 2015 and has held it in 14 quarters since. The position peaked at $15.6M in Q4 2017. 49 funds tracked by Wall St. Rank hold CDTX as of Q1 2019.

  • BB Biotech held 114,764 shares of Cidara Therapeutics worth $6.08M as of Q1 2019.
  • BB Biotech left its Cidara Therapeutics share count unchanged in Q1 2019.
  • Cidara Therapeutics made up 0.15% of BB Biotech's portfolio in Q1 2019, its #33 holding.
  • BB Biotech first reported a position in Cidara Therapeutics in Q4 2015 and has held it in 14 quarters since.
  • BB Biotech's Cidara Therapeutics position peaked at $15.6M in Q4 2017.
  • 49 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2019.

Based on BB Biotech's 13F filing for Q1 2019, filed 13 May 2019.